Kilitch Drugs (India) Limited (KILITCH) Fair Value & Analysis
Healthcare · IN · Market cap ₹6.9B
Fair value as of: Jul 3, 2026
From 16 valuation models · updated today
Share price +9.1% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹130.09 – ₹254.80 · fair‑value band ₹110.01 – ₹201.62 · the ₹196.99 price screens above the ₹146.68 fair value. As of Jul 3, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Kilitch Drugs (India) Limited (KILITCH) currently trades at ₹196.99, while our model-based Fair Value estimate is ₹146.68 — implying the stock looks roughly 25.5% overvalued today. We read business quality at 39/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, Kilitch Drugs (India) Limited generated revenue of ₹2.4B at a net margin of 12.8%. Revenue grew 46.3% year over year. It earns a return on equity of 12.4%. Net debt stands at ₹719M. Fundamentals as of Jul 3, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 3, 2026. TTM = trailing twelve months.
About the company
Kilitch Drugs (India) Limited engages in the development and operation of the pharmaceutical business in India and internationally. The company offers various parenteral, nasal, and topical products, such as liquid ampoules, vials, dry powder injectables, and metered nasal drops for gastroenterology, non-steroidal anti-inflammatory, anticonvulsant/antiepileptic, anti-malarial, aminoglycoside, antibacterial, anti-hypertensive, anti-infective, diagnostic, sympathomimetic, local anesthetic, neurotonic, uterine stimulant, external preparation, anticoagulant, narcotic, oncology, ophthalmic, antifungal, corticosteroid, anticoagulant, and other applications, as well as vaccines, veterinary products, iron supplements for anemia, Klavmox, and Onecef. It also provides oral formulations, including tablets, capsules, dry syrup, and oral powder for antibiotic, anti-diabetic, cardiovascular, and other areas; effervescent tablets and powders, such as Roipar, Duregra, and Roivit; and nutritional …
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Kilitch Drugs (India) Limited reported revenue of ₹2.4B in FY2026 versus ₹1.1B in FY2022, a compound +19.8%/yr. Reported net income was ₹302M in FY2026, compounding +42.3%/yr from FY2022.
Is KILITCH fairly valued? → Check now
Similar stocks
6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 3, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 1276 | HK$57.85 | HK$29.84 | -48% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,782 | ₹915.92 | -49% |
| Zoetis Inc Z1TS34 | R$24.45 | R$6.33 | -74% |
| Hansoh Pharmaceutical Group 3692 | HK$29.32 | HK$23.94 | -18% |
| Divi's Laboratories Limited DIVISLAB | ₹6,623 | ₹1,461 | -78% |
| Swedish Orphan Biovitrum AB SOBI | kr 444.80 | kr 440.64 | -1% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Kilitch Drugs (India) Limited (KILITCH) undervalued?
What is the fair value of KILITCH?
What is the quality score of KILITCH?
What is the revenue of Kilitch Drugs (India) Limited (KILITCH)?
What is the net profit margin of KILITCH?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.